Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia.
Face-to-face interviews and meetings with more than 160 policymakers and other influential professionals in seven large Asian countries (Bangladesh, China, India, Indonesia, Pakistan, Thailand and Vietnam) were conducted to survey opinions regarding the need for, and potential uses of new-generation vaccines against cholera, typhoid fever and shigellosis. Despite several barriers to their uptake--notably uncertainty of the burden of enteric diseases; preference for water, sanitation and other environmental improvements over vaccination for disease control; and high prices of the current vaccines relative to basic EPI vaccines, and their moderate protection levels--considerable interest was found in the targeted use of Vi typhoid vaccine in most countries, followed by (future) Shigella and oral cholera vaccines. The introduction of these vaccines in Asia could be greatly facilitated by country-specific evidence of disease burden, local or regional vaccine production, field studies demonstrating their safety and efficacy in local populations, evidence of potential economic savings from vaccination, and effective dissemination of research results to all those who make or influence immunization policy.
DeRoeck
Denise
D
International Vaccine Institute, San 4-8 Bongcheon-7-dong, Kwanak-gu, Seoul 151-818, South Korea. denise.deroeck@yahoo.com
Clemens
John D
JD
Nyamete
Andrew
A
Mahoney
Richard T
RT
D000288:Administrative Personnel; D001208:Asia; D022121:Cholera Vaccines / Q000276:immunology*; D017281:Cost of Illness; D006801:Humans; D022281:Shigella Vaccines / Q000276:immunology*; D014436:Typhoid-Paratyphoid Vaccines / Q000276:immunology*
D022121:Cholera Vaccines; D022281:Shigella Vaccines; D014436:Typhoid-Paratyphoid Vaccines